SCHEMBL10114513

SCHEMBL10114513

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
PTPN1 P18031 2/20 0.59
MITF O75030 1/20 0.58
RAB9A P51151 3/20 0.57
NPC1 O15118 2/20 0.57
ATM Q13315 1/20 0.57
POLB P06746 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
SNCA P37840 1/20 0.52
PTPN6 P29350 1/20 0.52
PTPN11 Q06124 1/20 0.52
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NOS1 P29475 1/20 0.51
NOS2 P35228 1/20 0.51
CXCR2 P25025 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116240 0.92 MEN1 (0.55) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL10116349 0.89 MEN1 (0.49) MEN1KMT2APTPN1MITFRAB9A
SCHEMBL10114489 0.87 TRPV1 (0.68) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL10116183 0.87 NPC1 (0.67) MEN1KMT2ARAB9ANPC1SNCA
SCHEMBL10116238 0.87 KDM4E (0.65) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL10116182 0.87 KMT2A (0.57) MEN1KMT2APTPN1RAB9ANPC1
SCHEMBL10116194 0.87 MEN1 (0.65) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL10116191 0.85 NPC1 (0.66) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL10116235 0.85 MEN1 (0.52) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL10116397 0.85 KMT2A (0.49) MEN1KMT2ARAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MEN1 2876/4885KMT2A 2912/4885PTPN1 312/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2932/4885KMT2A 2768/4885PTPN1 353/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2926/4885KMT2A 2953/4885PTPN1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.